Jonas Wallvik

Summary

Affiliation: Sundsvall Hospital
Country: Sweden

Publications

  1. ncbi request reprint Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes
    Jonas Wallvik
    Division of Hematology, Department of Medicine, Sundsvall Hospital, Sweden
    Eur J Haematol 68:180-5. 2002
  2. pmc Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics
    Jonas Wallvik
    Division of Hematology, Department of Medicine at Sundsvall Hospital, Sundsvall, Sweden
    Scand J Prim Health Care 25:123-8. 2007
  3. doi request reprint Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions
    Herman Nilsson-Ehle
    Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
    Eur J Haematol 87:244-52. 2011
  4. doi request reprint Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
    Michael Grövdal
    Division of Haematology, Department of Medicine, Centre for Experimental Haematology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Br J Haematol 150:293-302. 2010
  5. ncbi request reprint Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients
    Karin Karlsson
    Department of Haematology, University Hospital, Linkoping, Sweden
    Br J Haematol 116:538-48. 2002
  6. ncbi request reprint Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome
    Michael Grövdal
    Division of Haematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Denmark
    Clin Cancer Res 13:7107-12. 2007

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes
    Jonas Wallvik
    Division of Hematology, Department of Medicine, Sundsvall Hospital, Sweden
    Eur J Haematol 68:180-5. 2002
    ..007). Our data facilitate the optimal selection of MDS patients suitable for EPO treatment and pinpoint S-EPO as a powerful predictor of response and overall survival in MDS...
  2. pmc Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics
    Jonas Wallvik
    Division of Hematology, Department of Medicine at Sundsvall Hospital, Sundsvall, Sweden
    Scand J Prim Health Care 25:123-8. 2007
    ..To examine determinants of bleeding complications during warfarin treatment in an unselected patient population and evaluate possible differences in safety between specialized anticoagulation clinics and primary healthcare centres...
  3. doi request reprint Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions
    Herman Nilsson-Ehle
    Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
    Eur J Haematol 87:244-52. 2011
    ..The objective for this prospective phase II Nordic multicentre trial was to assess QoL, response rate and physical function in elderly anaemic MDS patients treated to a target Hb level of >120 g/L...
  4. doi request reprint Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
    Michael Grövdal
    Division of Haematology, Department of Medicine, Centre for Experimental Haematology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Br J Haematol 150:293-302. 2010
    ..5 and 30% of the cycles, respectively, while haemoglobin levels increased during treatment. 5-azacytidine treatment is safe, feasible and may be of benefit in a subset of patients...
  5. ncbi request reprint Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients
    Karin Karlsson
    Department of Haematology, University Hospital, Linkoping, Sweden
    Br J Haematol 116:538-48. 2002
    ..Cladribine used as a single agent is an effective treatment with an acceptable safety profile for pretreated and untreated B-CLL. The achievement of complete remission was not a prerequisite for long-term survival...
  6. ncbi request reprint Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome
    Michael Grövdal
    Division of Haematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Denmark
    Clin Cancer Res 13:7107-12. 2007
    ..This study was designed to assess the effect of methylation status on the outcome of conventional induction chemotherapy...